Companies › Laboratorio Elea Phoenix
2 active drug programs in 79 registered trials: 48 Phase 2, 19 Phase 1, 11 Phase 3, 1 Phase 4; Infectious disease, Neurology, Genitourinary, Hematology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Benznidazole (2 weeks) Antiparasitic agent active against Trypanosoma cruzi | – | Phase 3 | Chagas Disease | Dec 2026 |
| Cannabidiol Cannabinoid CB1 receptor negative allosteric modulator | CNR1 | Phase 2 | Parkinson Disease; Phobia, Social; Acute Radicular Back Pain; Early Psychosis … | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05742724 | Cannabidiol | Phase 1 | Cannabis | Genitourinary | Feb 2024 |
| NCT05092191 | Cannabidiol | Phase 2 | Multiple Sclerosis | Neurology | Apr 2025 |
| NCT04517799 | Cannabidiol | Phase 2 | Autism | Psychiatry | Aug 2025 |
| NCT06574100 | Cannabidiol | Phase 1 | Pharmacokinetics | Other | Nov 2025 |
| NCT04105231 | Cannabidiol | Phase 2 | Dual Diagnosis | Psychiatry | Nov 2025 |
| NCT04816994 | Cannabidiol | Phase 3 | Acute Radicular Back Pain | Other | Dec 2025 |
| NCT04550377 | Cannabidiol | Phase 2 | Post Traumatic Stress Disorder | Neurology | Mar 2026 |
| NCT05860699 | Cannabidiol | Phase 2 | Severe Alcohol Use Disorder (DSM 5) | Psychiatry | May 2026 |
| NCT07570472 | Cannabidiol | Phase 2 | Sleep Quality | Other | May 2026 |
| NCT07498023 | Cannabidiol | Phase 1 | Fibromyalgia | Other | Jul 2026 |
| NCT06629389 | Cannabidiol | Phase 2 | Parkinson Disease | Neurology | Nov 2026 |
| NCT06629389 | Cannabidiol | Phase 2 | Parkinson Disease | Neurology | Nov 2026 |
| NCT06629389 | Cannabidiol | Phase 2 | Parkinson Disease | Neurology | Nov 2026 |
| NCT03984565 | Cannabidiol | Phase 2 | Chronic Pain | Other | Nov 2026 |
| NCT04897516 | Benznidazole (2 weeks) | Phase 3 | Chagas Disease | Infectious disease | Dec 2026 |
| NCT04897516 | Benznidazole (2 weeks) | Phase 3 | Chagas Disease | Infectious disease | Dec 2026 |
| NCT04897516 | Benznidazole (2 weeks) | Phase 3 | Chagas Disease | Infectious disease | Dec 2026 |
| NCT05803434 | Cannabidiol | Phase 2 | Epilepsy | Neurology | Dec 2026 |
| NCT04411225 | Cannabidiol | Phase 3 | Early Psychosis | Psychiatry | Dec 2026 |
| NCT06477406 | Cannabidiol | Phase 2 | Endometriosis | Genitourinary | Dec 2026 |
| NCT05457465 | Cannabidiol | Phase 2 | Bipolar Disorder | Psychiatry | Dec 2026 |
| NCT06014424 | Cannabidiol | Phase 2 | Alzheimer Disease | Neurology | Dec 2026 |
| NCT06381791 | Cannabidiol | Phase 1 | Shoulder Osteoarthritis | Immunology | Dec 2026 |
| NCT05969314 | Cannabidiol | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT06218056 | Cannabidiol | Phase 2 | Tobacco Use Disorder | Psychiatry | Dec 2026 |
| NCT06672666 | Cannabidiol | Phase 2 | Anxiety | Psychiatry | Dec 2026 |
| NCT06099379 | Cannabidiol | Phase 1 | Cannabis | Psychiatry | Dec 2026 |
| NCT06099379 | Cannabidiol | Phase 1 | Cannabis | Psychiatry | Dec 2026 |
| NCT07298408 | Cannabidiol | Phase 1 | Diabetic Peripheral Neuropathic Pain (DPN) | Neurology | Dec 2026 |
| NCT06414473 | Cannabidiol | Phase 1 | Osteoarthritis, Knee | Immunology | Dec 2026 |
| NCT06512389 | Cannabidiol | Phase 2 | Alcohol Use Disorder | Psychiatry | Jan 2027 |
| NCT06930703 | Cannabidiol | Phase 1 | Sickle Cell Disease | Hematology | Feb 2027 |
| NCT04992624 | Cannabidiol | Phase 2 | Osteoarthritis, Knee | Immunology | Mar 2027 |
| NCT05613608 | Cannabidiol | Phase 2 | Alcohol Use Disorder | Psychiatry | Apr 2027 |
| NCT06333041 | Cannabidiol | Phase 2 | Sanfilippo Syndrome | Metabolic and endocrine | Apr 2027 |
| NCT05649059 | Cannabidiol | Phase 4 | Phobia, Social | Psychiatry | May 2027 |
| NCT06946940 | Cannabidiol | Phase 2 | Fibromyalgia | Other | May 2027 |
| NCT06448923 | Cannabidiol | Phase 2 | Fracture | Immunology | Jun 2027 |
| NCT05067387 | Cannabidiol | Phase 1 | Drug Abuse | Psychiatry | Jun 2027 |
| NCT06859723 | Cannabidiol | Phase 1 | Abuse Cannabis | Psychiatry | Jul 2027 |
| NCT06859723 | Cannabidiol | Phase 1 | Abuse Cannabis | Psychiatry | Jul 2027 |
| NCT06940674 | Cannabidiol | Phase 3 | Opioid Use Disorder (OUD) | Psychiatry | Jul 2027 |
| NCT05269628 | Cannabidiol | Phase 2 | Multiple Sclerosis | Neurology | Aug 2027 |
| NCT07123467 | Cannabidiol | Phase 3 | Generalized Anxiety Disorder (GAD) | Psychiatry | Aug 2027 |
| NCT05020028 | Cannabidiol | Phase 2 | Knee Arthritis | Immunology | Sep 2027 |
| NCT05629702 | Cannabidiol | Phase 2 | Glioblastoma | Oncology | Oct 2027 |
| NCT05514899 | Cannabidiol | Phase 2 | HIV | Infectious disease | Oct 2027 |
| NCT07668856 | Cannabidiol | Phase 3 | Refractory Epilepsy in Children | Neurology | Nov 2027 |
| NCT04482244 | Cannabidiol | Phase 2 | Advanced Breast Cancer | Oncology | Dec 2027 |
| NCT07245238 | Cannabidiol | Phase 3 | Mediciine | Immunology | Dec 2027 |
| NCT02926859 | Cannabidiol | Phase 2 | Schizophrenia | Psychiatry | Dec 2027 |
| NCT06731894 | Cannabidiol | Phase 2 | Breast Carcinoma | Oncology | Jan 2028 |
| NCT06778564 | Cannabidiol | Phase 3 | Psychosis | Psychiatry | Feb 2028 |
| NCT06137365 | Cannabidiol | Phase 2 | Obesity | Metabolic and endocrine | Mar 2028 |
| NCT06107062 | Cannabidiol | Phase 2 | Cannabis Use Disorder | Psychiatry | Mar 2028 |
| NCT06107062 | Cannabidiol | Phase 2 | Cannabis Use Disorder | Psychiatry | Mar 2028 |
| NCT06845124 | Cannabidiol | Phase 2 | Alcohol Addiction | Psychiatry | Apr 2028 |
| NCT05822362 | Cannabidiol | Phase 2 | Mild Cognitive Impairment | Neurology | Apr 2028 |
| NCT06840899 | Cannabidiol | Phase 2 | Supra-sacral Spinal Cord Injury | Neurology | May 2028 |
| NCT06266611 | Cannabidiol | Phase 2 | Sleep | Psychiatry | May 2028 |
The 60 nearest readouts of 79 trials; the rest in the app.
Jazz Pharmaceuticals IGC Pharma Sinfatin Zynerba Pharmaceuticals Skye Bioscience PleoPharma Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed
Zynerba Pharmaceuticals NeuroTherapia Vertanical Bazelet Nehushtan IGC Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.